IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens

• Main Authors: Nicos Karasavvas, Chitraporn Karnasuta, Hathairat Savadsuk, Sirinan Madnote, Dutsadee Inthawong, Somsak Chantakulkij, Surawach Rittiroongrad, Sorachai Nitayaphan, Punnee Pitisuttithum, Prasert Thongcharoen, Vinai Siriyanon, Charla A. Andrews, Susan W. Barnett, James Tartaglia, Faruk Sinangil, Donald P. Francis, Merlin L. Robb, Nelson L. Michael, Viseth Ngauy, Mark S. De Souza, Robert M. Paris, Jean Louis Excler, Jerome H. Kim, Robert J. O'Connell
• Format: Journal
• Published: 2018
• Subjects: Agricultural and Biological Sciences
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84946706967&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/44123
• Institution: Chiang Mai University

© Copyright 2015, Mary Ann Liebert, Inc. 2015. RV144 correlates of risk analysis showed that IgG antibodies to gp70V1V2 scaffolds inversely correlated with risk of HIV acquisition. We investigated IgG antibody responses in RV135 and RV132, two ALVAC-HIV prime-boost vaccine trials conducted in Thailand prior to RV144. Both trials used ALVAC-HIV (vCP1521) at 0, 1, 3, and 6 months and HIV-1 gp120MNgD and gp120A244gD in alum (RV135) or gp120SF2 and gp120CM235 in MF59 (RV132) at 3 and 6 months. We assessed ELISA binding antibodies to the envelope proteins (Env) 92TH023, A244gD and MNgD, cyclicV2, and gp70V1V2 CaseA2 (subtype B) and 92TH023 (subtype CRF01-AE), and Env-specific IgG1 and IgG3. Antibody responses to gp120 A244gD, MNgD, and gp70V1V2 92TH023 scaffold were significantly higher in RV135 than in RV132. Antibodies to gp70V1V2 CaseA2 were detected only in RV135 vaccine recipients and IgG1 and IgG3 antibody responses to A244gD were significantly higher in RV135. IgG binding to gp70V1V2 CaseA2 and CRF01-AE scaffolds was higher with the AIDSVAX ® B/E boost but both trials showed similar rates of antibody decline post-vaccination. MF59 did not result in higher IgG antibody responses compared to alum with the antigens tested. However, notable differences in the structure of the recombinant proteins and dosage used for immunizations may have contributed to the magnitude and specificity of IgG induced by the two trials.